4.22
0.07 (1.69%)
| Previous Close | 4.15 |
| Open | 4.20 |
| Volume | 1,740,458 |
| Avg. Volume (3M) | 3,583,292 |
| Market Cap | 715,017,344 |
| Price / Earnings (TTM) | 14.07 |
| Price / Earnings (Forward) | 14.20 |
| Price / Sales | 4.04 |
| Price / Book | 6.14 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 28.19% |
| Operating Margin (TTM) | 44.43% |
| Diluted EPS (TTM) | 0.480 |
| Quarterly Revenue Growth (YOY) | 22.80% |
| Quarterly Earnings Growth (YOY) | 70.60% |
| Total Debt/Equity (MRQ) | 32.53% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -81.23 M |
| Levered Free Cash Flow (TTM) | -53.07 M |
| Return on Assets (TTM) | 15.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CytomX Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 0.00 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 47.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (HC Wainwright & Co., 136.97%) | Buy |
| Median | 6.00 (42.18%) | |
| Low | 6.00 (Cantor Fitzgerald, 42.18%) | Buy |
| 6.00 (Barclays, 42.18%) | Buy | |
| Average | 7.33 (73.70%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Nov 2025 | 10.00 (136.97%) | Buy | 4.10 |
| Barclays | 21 Oct 2025 | 6.00 (42.18%) | Buy | 3.62 |
| 17 Sep 2025 | 3.50 (-17.06%) | Buy | 1.93 | |
| Cantor Fitzgerald | 22 Sep 2025 | 6.00 (42.18%) | Buy | 2.06 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Nov 2025 | Announcement | CytomX Therapeutics to Present at Upcoming December Investor Conferences |
| 13 Nov 2025 | Announcement | CytomX Therapeutics to Present at the Jefferies London Healthcare Conference |
| 06 Nov 2025 | Announcement | CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update |
| 04 Nov 2025 | Announcement | CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting |
| 30 Oct 2025 | Announcement | CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 20 Oct 2025 | Announcement | CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer |
| 28 Aug 2025 | Announcement | CytomX Therapeutics to Present at Upcoming September Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |